Table 2.

Adjusted HRs for Ventricular Tachycardia and Sudden Cardiac Arrest

Group	Comparison	HR (95% CI)
Ventricular tachycardia
HFrEF	HFrEF vs no HF	7.00 (6.10-8.02)
HFpEF	HFpEF vs no HF	1.99 (1.70-2.32)
Taking D or S	Taking D or S vs not taking D or S	2.47 (1.89-3.23)
HFrEF taking D or S	HFrEF taking D or S vs HFrEF not taking D or S	1.53 (1.07-2.20)
HFpEF taking D or S	HFpEF taking D or S vs HFpEF not taking D or S	2.34 (1.11-4.95)
Sudden cardiac arrest
HFrEF	HFrEF vs no HF	5.19 (4.10-6.57)
HFpEF	HFpEF vs no HF	2.53 (1.98-3.23)
Taking D or S	Taking D or S vs not taking D or S	1.39 (0.70-2.76)
HFrEF taking D or S	HFrEF taking D or S vs HFrEF not taking D or S	1.82 (0.60-5.52)
HFpEF taking D or S	HFpEF taking D or S vs HFpEF not taking D or S	0.86 (0.33-2.24)

D = dofetilide; S = sotalol; other abbreviations as in Table 1.

The multinomial propensity scoremethod was used to select potential covariates (listed in Supplemental Tables 7 and 8), and any characteristics with SMDs larger than 0.1 (listed in Supplemental Tables 7 and 8) were incorporated into the final model for double adjustment. The inverse probability of treatment weighting was used to stabilize the covariates-induced differences and survival analysis for the recurrent events model was performed. HFrEF, HFpEF, and taking D or S are the main effects, and HFrEF taking D or S and HFpEF taking D or S are the interaction terms in the model.